L-glycero-b-L-manno-Heptopyranosylamine,4-deoxy-4-[[2-[[(2E,4E)-1-oxo-2,4-tetradecadien-1-yl]amino]acetyl]amino]-N-1H-purin-6-yl-
Modify Date: 2024-01-19 12:44:09
![L-glycero-b-L-manno-Heptopyranosylamine,4-deoxy-4-[[2-[[(2E,4E)-1-oxo-2,4-tetradecadien-1-yl]amino]acetyl]amino]-N-1H-purin-6-yl- Structure](https://www.chemsrc.com/caspic/284/151276-95-8.png)
L-glycero-b-L-manno-Heptopyranosylamine,4-deoxy-4-[[2-[[(2E,4E)-1-oxo-2,4-tetradecadien-1-yl]amino]acetyl]amino]-N-1H-purin-6-yl- structure
|
Common Name | L-glycero-b-L-manno-Heptopyranosylamine,4-deoxy-4-[[2-[[(2E,4E)-1-oxo-2,4-tetradecadien-1-yl]amino]acetyl]amino]-N-1H-purin-6-yl- | ||
|---|---|---|---|---|
| CAS Number | 151276-95-8 | Molecular Weight | 589.68400 | |
| Density | 1.34g/cm3 | Boiling Point | 1007.6ºC at 760 mmHg | |
| Molecular Formula | C28H43N7O7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 563.2ºC | |
Use of L-glycero-b-L-manno-Heptopyranosylamine,4-deoxy-4-[[2-[[(2E,4E)-1-oxo-2,4-tetradecadien-1-yl]amino]acetyl]amino]-N-1H-purin-6-yl-KRN5500 (NSC 650426), a Spicamycin (HY-127130) derivative and a nucleoside-like antibiotic with anti-tumor activity. KRN5500 also induces apoptosis via the down-regulation of Bcl-2 expression. KRN5500 shows a significant efficacy in the human tumor xenograft model in mice[1][2]. |
| Name | (2E,4E)-N-[2-[[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide |
|---|---|
| Synonym | More Synonyms |
| Description | KRN5500 (NSC 650426), a Spicamycin (HY-127130) derivative and a nucleoside-like antibiotic with anti-tumor activity. KRN5500 also induces apoptosis via the down-regulation of Bcl-2 expression. KRN5500 shows a significant efficacy in the human tumor xenograft model in mice[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Bcl-2 |
| In Vitro | KRN5500 (10-160 ng/mL; 0-5 d) 有效抑制 NB4、NKM-1 和 HL-60 细胞的增殖和活力[1]。 KRN5500 (40 ng/mL, 160 ng/mL; 48 h) 诱导 NB4、HL-60 和 NKM-1 细胞凋亡[1]。 KRN5500 (40 ng /mL, 80 ng /mL; 36 h) 下调 NB4 细胞中 Bcl-2 的表达[1]。 Cell Viability Assay[1] Cell Line: NB4, HL-60, NKM-1, NOP-1 and Daudi cells Concentration: 10 ng/mL, 20 ng/mL, 40 ng/mL, 80 ng/mL, 160 ng/mL Incubation Time: 0, 1, 2, 3, 4, and 5 days or 72 h Result: Completely inhibited cell proliferation and viability of NB4 and NKM-1 at about 80 ng/mL, of HL-60 at 160 ng/mL. Inhibited cells viability of IC50s of 51.6 ng/mL, 89.7 ng/mL, 66.5 ng/mL, 277.0 ng/mL, 242.1 ng/mL, respectively. Western Blot Analysis[1] Cell Line: NB4 cells Concentration: 40 ng/mL, 80 ng/mL Incubation Time: 36 h Result: Reduced the Bcl-2 expression without affecting Bcl-xL and Bax expression. |
| In Vivo | KRN5500 (4 mg/kg; 腹腔注射; 每天 1 次，共 5 天) 显示抗肿瘤活性，导致一些小鼠肿瘤和人肿瘤异种抑制模型中的肿瘤重量下降[2]。 Animal Model: Mouse model with murine tumors and human tumor xenografts[2] Dosage: 4 mg/kg Administration: Intraperitoneal injection; once daily for 5 days Result: Prolonged the survival of P388 leukemia- and B16 melanoma-bearing mice but lacked marginally effective on colon adenocarcinoma. Decreased tumor weight in 10 human stomach, 14 colon and 2 esophageal cancers. |
| References |
| Density | 1.34g/cm3 |
|---|---|
| Boiling Point | 1007.6ºC at 760 mmHg |
| Molecular Formula | C28H43N7O7 |
| Molecular Weight | 589.68400 |
| Flash Point | 563.2ºC |
| Exact Mass | 589.32200 |
| PSA | 214.84000 |
| LogP | 1.27360 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.623 |
| KRN5500 |
| 4-Deoxy-N-(7H-purin-6-yl)-4-(((2,4-tetradecadienoylamino)acetyl)amino)heptopyranosylamine |
| Spicamycin analog |